ICER Releases Draft Report on Cystic Fibrosis Therapies

February 21, 2020

The Institute for Clinical and Economic Review (ICER) on Thursday, Feb. 20, released a draft evidence report on treatments for cystic fibrosis.

The report assesses the effectiveness and value of Vertex’s Trikafta, as well as considers new data on three other drugs from Vertex: Symdeko, Orkambi and Kalydeco.

According to a press release, ICER is accepting public input on the draft report until 5 p.m. EST March 18.

To read the report, click here.

Click here to read the full press release.

Share This Story!